Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert
News May 30, 2013
Agere Pharmaceuticals, Inc. announced today that Mr. Michael R. Deperro has joined the company as VP of Operations. The company added cGMP manufacturing capabilities in 2011, and since has expanded facilities to produce Phase I through Phase IIb clinical trials materials for clients.
“Mike brings Agere extensive experience and a strong track record for successfully managing and growing cGMP operations,” commented Marshall Crew, President and CEO of Agere. “He will play a key role as we continue our rapid growth to meet the rigorous expectations of our clients.”
Mr. Deperro has held director and GM-level manufacturing positions at numerous pharmaceutical companies including Alkermes and Taro Pharmaceuticals. He has also been responsible for implementing research and manufacturing infrastructure and operations domestically and abroad for large pharmaceutical and biotechnology companies including Merck and Co. and Novartis. Mr. Deperro’s career focus has been in the areas of drug development, new product launch, and commercialization. His regulatory compliance knowledge of FDA, MHRA, PMDA and ANVISA agencies enhances Agere’s strength in meeting the needs of a growing international client base. Mr. Deperro holds the Bachelor of Science degree in Mechanical Engineering from Notre Dame University, and has earned the Six Sigma Yellow Belt status from the International Society for Six Sigma Certifications.
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018